Regulus Therapeutics (RGLS) Stock Price, Quote & News

Company Profile

Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was formerly known as Regulus Therapeut...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 202 6300

Website: www.regulusrx.com

Address:

4224 Campus Point Court, Suite 210, San Diego, United States

Gemini367 Jan. 7 at 11:20 AM

$VTYX $RGLS $AKRO $VKTX . Congrats to all, who are still holding VTYX. Potential bidding war can can send it much higher. Good luck.

0 · Reply

BinaryLogic Jan. 7 at 2:25 AM

$VTYX [Correct] Congratulations to those who listened from $1.0-1.7. You only had to wait 6-12mos. Concurrently-you could have done well from my analyses on $RANI from $0.4, $IMRX from $1.0, SCNX from $0.5->3.0, $RGLS from $0.8, $VKTX from $17. Again-invest to your own risk tolerance and time horizon, diversify your positions and do your own analysis to build your conviction. https://www.investing.com/news/stock-market-news/ventyx-biosciences-stock-surges-after-eli-lilly-acquisition-talks-93CH-4433423

0 · Reply

RicardoMann Dec. 17 at 10:22 AM

$RGLS

0 · Reply

Runescapeftw1337 Dec. 10 at 3:33 PM

$RGLS

0 · Reply

BinaryLogic Dec. 9 at 2:49 AM

$VTYX $VIGL $RGLS

1 · Reply

BinaryLogic Nov. 25 at 12:44 AM

$COCH So far this year, I have cited $RANI at $0.4, $VTYX from $1.0-1.7, $IMRX from $1.5 and $RGLS from $0.8. You can burn through my post history to confirm each one. COCH is yet another Company (IMO) with tremendous upside from its current valuation. 50-100% upside just to reach institutional equity placements, while success on Acclaim study makes this 5-10X more valuable (IMO). The Company is trading at/around its ATL, Oversold and Undervalued. The balance sheet has been strengthened materially by debt elimination and equity placements, as-noted. Pivotal trial underway while COCH builds its global IP.

1 · Reply

Dazedconfused12 Nov. 23 at 3:08 AM

$RGLS what is a CVR?

0 · Reply

Heypentaco Oct. 26 at 5:46 PM

$SLS My most notable ( to me ) indicator of a buyout went off here about 3 months ago. It is usually 3 to 6 month thereafter that I start really watching for the announcement. Check out $RGLS . The indicator held true there. Enjoy what my opinion says is coming here. The CEO ... playing with big dogs on LinkedIn? LOL...Duh.

1 · Reply

voiceofreason333 Sep. 17 at 3:04 PM

$GRRR all I can think of is early year $RGLS squeeze

0 · Reply

WilliamAnastasiades488 Aug. 18 at 2:46 PM

$RGLS shows that preclinical biotech stories need constant momentum. KLTO’s update provided exactly that by advancing KLTO-202 production.

0 · Reply

Novartis completes acquisition of Regulus Therapeutics

NVS

Jun 25, 2025, 1:00 AM EDT - 7 months ago

Novartis announces expiration of Regulus Therapeutics tender offer

NVS

May 27, 2025, 7:56 AM EDT - 8 months ago

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

NVS

May 8, 2025, 4:05 PM EDT - 8 months ago

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

May 4, 2025, 12:25 PM EDT - 9 months ago

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

Apr 30, 2025, 12:24 PM EDT - 9 months ago

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher

NVS

Apr 30, 2025, 11:22 AM EDT - 9 months ago

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

NVS

Apr 30, 2025, 7:50 AM EDT - 9 months ago

Novartis to Acquire Regulus in $1.7 Billion Deal

NVS

Apr 30, 2025, 7:25 AM EDT - 9 months ago

Novartis to buy Regulus Therapeutics for up to $1.7 billion

NVS

Apr 30, 2025, 7:10 AM EDT - 9 months ago

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

NVS

Apr 30, 2025, 7:00 AM EDT - 9 months ago

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

NVS

Apr 2, 2025, 8:00 AM EDT - 10 months ago

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

Mar 27, 2025, 12:59 PM EDT - 10 months ago

Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease

Mar 27, 2025, 7:00 AM EDT - 10 months ago

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Mar 13, 2025, 4:05 PM EDT - 10 months ago

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

Mar 4, 2025, 8:00 AM EST - 11 months ago

Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 1 year ago

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

Nov 26, 2024, 8:00 AM EST - 1 year ago

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Nov 7, 2024, 4:05 PM EST - 1 year ago

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes

May 16, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer

May 9, 2024, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

May 6, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series

Apr 10, 2024, 12:51 PM EDT - 1 year ago

Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

Mar 12, 2024, 6:32 AM EDT - 2 years ago

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

Mar 12, 2024, 6:30 AM EDT - 2 years ago

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jan 2, 2024, 4:05 PM EST - 2 years ago

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Nov 22, 2023, 8:00 AM EST - 2 years ago

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 9, 2023, 4:05 PM EST - 2 years ago

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sep 20, 2023, 7:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sep 13, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Aug 23, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

Aug 2, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jul 18, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference

Jun 27, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jun 23, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D.

Jun 20, 2023, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital

Gemini367 Jan. 7 at 11:20 AM

$VTYX $RGLS $AKRO $VKTX . Congrats to all, who are still holding VTYX. Potential bidding war can can send it much higher. Good luck.

0 · Reply

BinaryLogic Jan. 7 at 2:25 AM

0 · Reply

RicardoMann Dec. 17 at 10:22 AM

$RGLS

0 · Reply

Runescapeftw1337 Dec. 10 at 3:33 PM

$RGLS

0 · Reply

BinaryLogic Dec. 9 at 2:49 AM

$VTYX $VIGL $RGLS

1 · Reply

BinaryLogic Nov. 25 at 12:44 AM

1 · Reply

Dazedconfused12 Nov. 23 at 3:08 AM

$RGLS what is a CVR?

0 · Reply

Heypentaco Oct. 26 at 5:46 PM

1 · Reply

voiceofreason333 Sep. 17 at 3:04 PM

$GRRR all I can think of is early year $RGLS squeeze

0 · Reply

WilliamAnastasiades488 Aug. 18 at 2:46 PM

$RGLS shows that preclinical biotech stories need constant momentum. KLTO’s update provided exactly that by advancing KLTO-202 production.

0 · Reply

Bjsanchez04 Jul. 30 at 3:28 PM

$RGLS what’s going on with this? Haven’t seen any movement.

1 · Reply

ted_the_trader Jul. 24 at 7:55 AM

$IXHL - I've noticed a similarity in price action with $RGLS during their acquisition by Novartis a couple of months ago. RGLS popped from $1 to $3 for no apparent reason and then a week later Novartis announced their acquisition at $7 (plus $7 in CVRs contingent to FDA approval). Most likely insiders leaked the news to friends and family which drove the price up before the announcement. Of course we don't know for sure if this is the case with $IXHL, but it's not impossible

2 · Reply

Gate1234 Jul. 12 at 10:17 AM

$ITRM $RGLS

1 · Reply

eskimo242 Jul. 10 at 11:59 AM

$ITRM For those who claim that there is no 6x-10x BO: This chart is our rolemodel. The value (and TAM) is what's important, not the current share price. Shortly before the BO, the price rises, creating your “only” 2x-3x increase on paper. However, the negotiations occurred when the price was low. Also, $RGLS dipped below $1 weeks before the BO.

4 · Reply

Gemini367 Jul. 2 at 12:39 PM

$RGLS is someone here, who already received the cash?

2 · Reply

BigBadBeethoven Jun. 26 at 7:20 PM

$RGLS Guys, don't forget that the $800 million up front payment that Novartis is making for RGLS is for $7 per share for about 70 million outstanding shares PLUS golden parachute packages for the 3 top Execs, lawyers, and I'm sure there's a zillion investment firms that they hired. So in these buyouts the lawyers and investment firms usually make more than we do. And as to the possible $900M to be paid in the future only if Farabursen hits its FDA milestone, that might very well be zero. In that case all the money that NVS is out is the initial $800 million

1 · Reply

Planetpaprika Jun. 26 at 5:27 PM

$RGLS Novartis yesterday announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis. https://www.novartis.com/news/media-releases/novartis-completes-acquisition-regulus-therapeutics

0 · Reply

attawfik Jun. 26 at 4:05 PM

$RGLS Dumb question but do we get to keep the shares after the $7 pay out ?

4 · Reply

Johnny76 Jun. 26 at 3:09 PM

$RGLS anyone here did the math? so we get $7/share plus $7 CVR plus milestone if reached ? Am I correct? Total of $24.55? That’s $1.7B deal?

1 · Reply

BinaryLogic Jun. 26 at 2:38 AM

$VTYX $RGLS $VIGL

0 · Reply

BigBadBeethoven Jun. 25 at 6:09 PM

$RGLS well it looks like the sale went through as they got about 75% of the shares and they only needed one share more than 50%. So if you're holding it you're going to get $7 cash PLUS a CVR for every share you own. Just remember that the CVR is nontradable. You're going to have to hold it in your account or wherever until Farabursen hits it's milestones or the CVR expires at $0. I personally think that drug is going to be a BLOCKBUSTER and I actually wanted to HOLD RGLS, because I think 2 years down the line RGLS would have easily hit $100 if the buyout hadn't happened. But I didn't have enough shares to stymie their efforts. Did anybody here have enough shares to do that? Not a rhetorical question LOL

1 · Reply

JG101 Jun. 25 at 4:12 PM

$DTIL Increase my position by 30%. These small biotech stocks are easy to manipulate on good news. Look what happened with the good news $RGLS had: stock down over 30% and the best entry point I’ve ever seen (and used generously) in biotech. A few months later they went from below 1$ to 7$ with a 7$ CVR…

1 · Reply

Market Cap	564.95M
Revenue (ttm)	0.00
Net Income (ttm)	-46.36M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	9,342,400
Avg Vol	2,425,440
Day's Range	N/A - N/A
Shares Out	69.23M
Stochastic %K	72%
Beta	0.35
Analysts	Sell
Price Target	$8.80